article thumbnail

Novavax’s updated Covid-19 vaccine receives FDA emergency use authorisation

Pharmaceutical Business Review

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. Following the EUA, the vaccine is also recommended by the US Centers for Disease Control and Prevention (CDC). Our updated vaccine targets JN.1, 1.” “Our updated vaccine targets JN.1,

article thumbnail

AstraZeneca Pauses Vaccine Trial for Safety Review

NY Times

The company halted late-stage trials of its coronavirus vaccine because of a serious suspected adverse reaction in a participant.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Moderna’s Covid-19/influenza vaccine phase III data highlights potential of mRNA technology for infectious diseases: GlobalData

Express Pharma

Moderna has announced positive Phase III data for its COVID-19/influenza combination vaccine, mRNA-1083. Stephanie Kurdach, Infectious Disease Analyst at GlobalData, comments, “Moderna’s mRNA-1083 combines the mRNA-1010 seasonal influenza vaccine candidate with the mRNA-1283 next-generation Covid-19 vaccine candidate.

article thumbnail

mRNA vaccine trial shows efficiency in older adults with RSV

European Pharmaceutical Review

mRNA-1345 demonstrated vaccine efficacy (VE) of 83.7 percent in Moderna’s mRNA vaccine Phase III trial targeting respiratory syncytial virus (RSV) in older adults. ” Moderna’s mRNA vaccine – mRNA-1345. mRNA-1345 is an investigational RSV vaccine. Moderna launches two new mRNA vaccine programmes.

Vaccines 105
article thumbnail

Moderna receives U.S. FDA approval for RSV vaccine mRESVIA(R)

Express Pharma

mRESVIA is Moderna’s second approved product and reportedly the only RSV vaccine available in single-dose pre-filled syringes Moderna, announced that the U.S. This approval is also the first time an mRNA vaccine has been approved for a disease other than COVID-19. The primary analysis with 3.7 per cent (95.88 per cent CI 66.0

article thumbnail

Health Canada approves Novavax’s Covid-19 vaccine for adolescents

Pharmaceutical Technology

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.

Vaccines 105
article thumbnail

EC approves Novavax’s Covid-19 vaccine CMA expansion for adolescents

Pharmaceutical Technology

The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.

Vaccines 105